Qualigen announces $4.5M private placement of Preferred Shares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 19 2024
0mins
Should l Buy ?
Qualigen Therapeutics Securities Offering: Qualigen Therapeutics has secured $4.5 million through the sale of 4,500 Series A-2 Preferred Shares, convertible into common shares at a price of $3.64 each.
Closing Details: The offering is expected to finalize around November 19, 2024, pending customary closing conditions, with Univest, LLC serving as the exclusive placement agent.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
